Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Drug inhibition profile prediction for NFκB pathway in multiple myeloma.

Peng H, Wen J, Li H, Chang J, Zhou X.

PLoS One. 2011 Mar 7;6(3):e14750. doi: 10.1371/journal.pone.0014750.

2.

An anti-leishmanial thiadiazine agent induces multiple myeloma cell apoptosis by suppressing the nuclear factor kappaB signalling pathway.

Chen G, Han K, Xu X, Du X, Zhang Z, Tang J, Shi M, Wang M, Li J, Cao B, Mao X.

Br J Cancer. 2014 Jan 7;110(1):63-70. doi: 10.1038/bjc.2013.711. Epub 2013 Nov 14.

3.

Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity.

Salem K, Brown CO, Schibler J, Goel A.

Exp Hematol. 2013 Feb;41(2):209-18. doi: 10.1016/j.exphem.2012.10.002. Epub 2012 Oct 11.

4.

Triptolide-induced apoptosis by inactivating nuclear factor-kappa B apoptotic pathway in multiple myeloma in vitro.

Zeng R, Zeng L, Chen Y, Zhao F, Li R, Wen L, Zhang C.

J Huazhong Univ Sci Technolog Med Sci. 2011 Aug;31(4):446-51. doi: 10.1007/s11596-011-0471-7. Epub 2011 Aug 7.

PMID:
21823003
5.

Importin β1 mediates nuclear factor-κB signal transduction into the nuclei of myeloma cells and affects their proliferation and apoptosis.

Yan W, Li R, He J, Du J, Hou J.

Cell Signal. 2015 Apr;27(4):851-9. doi: 10.1016/j.cellsig.2015.01.013. Epub 2015 Jan 30.

PMID:
25643631
6.

Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL.

Romagnoli M, Desplanques G, Maïga S, Legouill S, Dreano M, Bataille R, Barillé-Nion S.

Clin Cancer Res. 2007 Oct 15;13(20):6010-8.

7.

The receptor tyrosine kinase FGFR4 negatively regulates NF-kappaB signaling.

Drafahl KA, McAndrew CW, Meyer AN, Haas M, Donoghue DJ.

PLoS One. 2010 Dec 22;5(12):e14412. doi: 10.1371/journal.pone.0014412.

8.

Embelin suppresses osteoclastogenesis induced by receptor activator of NF-κB ligand and tumor cells in vitro through inhibition of the NF-κB cell signaling pathway.

Reuter S, Prasad S, Phromnoi K, Kannappan R, Yadav VR, Aggarwal BB.

Mol Cancer Res. 2010 Oct;8(10):1425-36. doi: 10.1158/1541-7786.MCR-10-0141. Epub 2010 Sep 8.

9.

The NF-kappaB inhibitor LC-1 has single agent activity in multiple myeloma cells and synergizes with bortezomib.

Walsby EJ, Pratt G, Hewamana S, Crooks PA, Burnett AK, Fegan C, Pepper C.

Mol Cancer Ther. 2010 Jun;9(6):1574-82. doi: 10.1158/1535-7163.MCT-10-0104. Epub 2010 Jun 1.

10.

Alkylating agents induce activation of NFkappaB in multiple myeloma cells.

Baumann P, Mandl-Weber S, Oduncu F, Schmidmaier R.

Leuk Res. 2008 Jul;32(7):1144-7. Epub 2008 Feb 20.

PMID:
18083229
12.

Cardamonin exerts potent activity against multiple myeloma through blockade of NF-κB pathway in vitro.

Qin Y, Sun CY, Lu FR, Shu XR, Yang D, Chen L, She XM, Gregg NM, Guo T, Hu Y.

Leuk Res. 2012 Apr;36(4):514-20. doi: 10.1016/j.leukres.2011.11.014. Epub 2012 Jan 4.

PMID:
22226224
13.

The IKK inhibitor Bay 11-7082 induces cell death independent from inhibition of activation of NFκB transcription factors.

Rauert-Wunderlich H, Siegmund D, Maier E, Giner T, Bargou RC, Wajant H, Stühmer T.

PLoS One. 2013;8(3):e59292. doi: 10.1371/journal.pone.0059292. Epub 2013 Mar 20.

14.

Nuclear factor-κB is involved in the protocadherin-10-mediated pro-apoptotic effect in multiple myeloma.

Li Z, Yang Z, Peng X, Li Y, Liu Q, Chen J.

Mol Med Rep. 2014 Aug;10(2):832-8. doi: 10.3892/mmr.2014.2285. Epub 2014 May 29.

PMID:
24888369
15.

The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFκB signalling pathway.

Smith EM, Zhang L, Walker BA, Davenport EL, Aronson LI, Krige D, Hooftman L, Drummond AH, Morgan GJ, Davies FE.

Oncotarget. 2015 Jul 10;6(19):17314-27.

16.

Dexamethasone treatment of tumor necrosis factor-alpha challenged organ of Corti explants activates nuclear factor kappa B signaling that induces changes in gene expression that favor hair cell survival.

Dinh CT, Bas E, Chan SS, Dinh JN, Vu L, Van De Water TR.

Neuroscience. 2011 Aug 11;188:157-67. doi: 10.1016/j.neuroscience.2011.04.061. Epub 2011 May 7.

PMID:
21571041
17.

Expression of GITR Enhances Multiple Myeloma Cell Sensitivity to Bortezomib.

Zhao Y, Zhang K, Li G, Zhang X, Shi D.

PLoS One. 2015 May 14;10(5):e0127334. doi: 10.1371/journal.pone.0127334. eCollection 2015.

18.
19.

A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo.

Watanabe M, Dewan MZ, Okamura T, Sasaki M, Itoh K, Higashihara M, Mizoguchi H, Honda M, Sata T, Watanabe T, Yamamoto N, Umezawa K, Horie R.

Int J Cancer. 2005 Mar 10;114(1):32-8.

20.

The peptide-semicarbazone S-2209, a representative of a new class of proteasome inhibitors, induces apoptosis and cell growth arrest in multiple myeloma cells.

Baumann P, Müller K, Mandl-Weber S, Leban J, Doblhofer R, Ammendola A, Baumgartner R, Oduncu F, Schmidmaier R.

Br J Haematol. 2009 Mar;144(6):875-86. doi: 10.1111/j.1365-2141.2008.07570.x. Epub 2009 Jan 16.

PMID:
19170678

Supplemental Content

Support Center